80.89 0.00 (0.00%)
After hours: 4:49PM EST
|Bid||79.20 x 1800|
|Ask||81.37 x 1100|
|Day's Range||80.38 - 82.74|
|52 Week Range||71.84 - 96.79|
|Beta (5Y Monthly)||1.03|
|PE Ratio (TTM)||39.46|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Incyte (Nasdaq:INCY) is proud to announce the opening call for submissions for its newly launched Incyte Ingenuity Award, an annual program created to support people living with graft-versus-host disease (GVHD), as well as their caregivers and physicians, by encouraging innovative and novel solutions for the challenges currently facing the GVHD community. Each year, the Incyte Ingenuity Award is expected to fund, up to $100,000, one innovative program, idea or initiative that fosters collaboration within the GVHD community to address a specific unmet need.
Incyte Announces Positive Topline Results from Phase 3 TRuE-AD Program evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis
Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs
Incyte (Nasdaq:INCY) announced today that it will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 at 11:20 a.m. ET in Boston.
Incyte Announces Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD5, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy of baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis (AD). The primary endpoint was defined by the proportion of patients achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) at Week 16.
Incyte Announces that the TRuE-AD2 Pivotal Trial of Ruxolitinib Cream Met its Primary Endpoint in Patients with Atopic Dermatitis
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD4, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy of baricitinib in combination with topical corticosteroids (TCS) for the treatment of adult patients with moderate to severe atopic dermatitis (AD) who were inadequate responders, intolerant or had contraindication to treatment with cyclosporine. The primary endpoint was defined by the proportion of patients achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) at Week 16.
Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2019 financial results conference call and webcast for 8:00 a.m. ET on Thursday, February 13, 2020.
Incyte Announces the Validation by the EMA of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma
Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease
Research from Taltz®, Olumiant® and mirikizumab highlight the impact Lilly's medicines may have for patients around the world INDIANAPOLIS , Oct. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) ...
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced the addition of immunology expert, Cara L. Haymaker, Ph.D., to its Scientific Advisory Board, effective immediately. Additionally, Dr. Bill Williams, BriaCell’s President & CEO, has been selected to lead the upcoming special joint issue of the prestigious, peer-reviewed journals, Frontiers in Pharmacology and Frontiers in Oncology with the research topic of 'Targeted Immunotherapy for Cancer'. Dr. Cara Haymaker is an assistant professor at Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center.